SCHEMBL20914154

SCHEMBL20914154

Cc1[nH]c2c(-c3ccccc3)c(C(F)(F)F)nn2c(=O)c1-c1nnc(C2CCCN(C(=O)OC(C)(C)C)C2)o1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 3/20 0.42
▸ HSD11B1 P28845 1/20 0.42
▸ PRMT5 O14744 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ APLNR P35414 1/20 0.37
▸ USP30 Q70CQ3 2/20 0.36
▸ P2RX7 Q99572 1/20 0.36
▸ BTK Q06187 1/20 0.36
▸ MAPT P10636 2/20 0.36
▸ ACKR3 P25106 1/20 0.36
▸ TLR8 Q9NR97 1/20 0.35
▸ TLR7 Q9NYK1 1/20 0.35
▸ HDAC6 Q9UBN7 2/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ HDAC3 O15379 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914075 0.92 SMN1; SMN2 (0.46) HPGDSPRMT5SMN1; SMN2GAATHRB
SCHEMBL20914353 0.91 HSD11B1 (0.44) HPGDSHSD11B1HDAC6HDAC3CYP2C9
SCHEMBL20913939 0.86 TSHR (0.42) GAAMAPT
SCHEMBL20914007 0.86 PLAT (0.43) HSD11B1GAAMAPTHDAC6HDAC3
SCHEMBL20914105 0.85 PLAT (0.42) HSD11B1GAAMAPTHDAC6HDAC3
SCHEMBL20914252 0.85 HSD11B1 (0.38) HSD11B1SMN1; SMN2GAAMAPTTLR8
SCHEMBL20914256 0.84 HDAC3 (0.43) MAPTHDAC6HDAC3CYP2C9HDAC1
SCHEMBL20913972 0.82 PLAT (0.42) HSD11B1TLR8TLR7
SCHEMBL20914350 0.81 PLAT (0.38) HSD11B1GAAMAPTHDAC6HDAC3
SCHEMBL20914226 0.81 PLAT (0.47) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 HPGDS 594/4885HSD11B1 3808/4885PRMT5 609/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 HPGDS 594/4885HSD11B1 3808/4885PRMT5 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback